The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CVAC | +100% | -93.63% | -42.34% | -90% |
| S&P | +13.14% | +87.24% | +13.37% | +102% |
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $63.26M | -88.3% |
| Gross Profit | $57.92M | -88.8% |
| Gross Margin | 91.57% | -3.4% |
| Market Cap | $1.21B | 84.0% |
| Market Cap / Employee | $1.23M | 0.0% |
| Employees | 983 | -16.1% |
| Net Income | $319.28M | -14.0% |
| EBITDA | -$6.70M | -101.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $488.91M | -20.5% |
| Accounts Receivable | $23.03M | 258.0% |
| Inventory | 0.6 | 21.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $35.60M | -8.6% |
| Short Term Debt | $5.60M | -4.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 14.14% | 0.8% |
| Return On Invested Capital | -28.30% | 62.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $31.71M | -91.7% |
| Operating Free Cash Flow | $32.04M | -91.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 4.21 | 3.05 | 5.68 | 7.50 | 40.25% |
| Price to Book | 0.95 | 0.77 | 1.75 | 1.74 | 113.03% |
| Price to Sales | 1.30 | 1.09 | 2.18 | 15.02 | 1251.34% |
| Price to Tangible Book Value | 0.98 | 0.80 | 1.82 | 1.81 | 113.50% |
| Price to Free Cash Flow TTM | 5.85 | 8.19 | 3.91 | 5.92 | - |
| Enterprise Value to EBITDA | -6.77 | -3.61 | -12.19 | -114.81 | -55924.86% |
| Free Cash Flow Yield | 17.1% | 12.2% | 25.6% | 16.9% | - |
| Return on Equity | 28.1% | 34.5% | 39.2% | 17.7% | 3.52% |
| Total Debt | $40.35M | $40.38M | $42.30M | $41.20M | -8.00% |
No podcast episodes available.
CVAC earnings call for the period ending March 31, 2022.
CVAC earnings call for the period ending September 30, 2021.
CVAC earnings call for the period ending March 31, 2021.
CVAC earnings call for the period ending September 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
